what is selank: Frequently asked questions

Assume the amidated form was used unless the methods section specifies otherwise. Russian studies from the Institute of Molecular Genetics (the peptide's origin) used 'Selank' as the primary identifier, with amidation implied as the default synthesis protocol. Western replication studies often added 'Amidate' for clarity when publishing in journals with stricter peptide nomenclature standards. Both refer to the same active compound tested in Phase II trials.

No. Assume it's the amidated form unless the certificate of analysis explicitly states otherwise. The 'Amidate' suffix is a clarifying descriptor used inconsistently across suppliers and literature. Check the molecular weight on the COA: Selank Amidate has a molecular mass of 751.887 g/mol due to the terminal amide group, while the free acid form (which would be inactive) has a slightly higher mass of 752.871 g/mol. HPLC-MS results showing 751.887 confirm you received the correct compound regardless of labelling.

Request certificates of analysis for both listings and compare the molecular weights and HPLC retention times. If the values are identical, they're selling the same peptide under two names. A red flag for supplier competence. If the weights differ, one product may be an inactive precursor or improperly synthesised batch. Legitimate research suppliers don't differentiate between Selank and Selank Amidate because there's no chemical basis for the distinction.

Mild nasal irritation occurs in approximately 5% of subjects in observational studies. Typically transient stinging or dryness lasting 5–10 minutes post-administration. This is usually attributable to the pH or osmolarity of the reconstitution solution rather than the peptide itself. Switching to sterile saline instead of bacteriostatic water for reconstitution reduces irritation in sensitive subjects. If irritation persists or worsens, discontinue use and consult the study protocol supervisor.

No published studies report adverse interactions between Selank and Semax, and anecdotal reports from research contexts suggest co-administration is well-tolerated. Both peptides increase BDNF expression and share intranasal administration, but their mechanisms diverge: Semax acts through ACTH-derived pathways affecting acetylcholine and dopamine, while Selank modulates IL-6 and enkephalin. In research settings where both peptides are used sequentially, allow 30–60 minutes between administrations to avoid nasal mucosal saturation and to distinguish individual compound effects during observation.

Refrigerate reconstituted Selank immediately. Peptide degradation accelerates above 8°C. Enzymatic hydrolysis of peptide bonds occurs faster at ambient temperature, and bacterial growth in bacteriostatic water becomes possible beyond 48 hours at room temperature. If reconstituted Selank was left at room temperature for fewer than 6 hours, refrigerate it immediately and use within the standard 28-day window. If left for more than 12 hours, peptide integrity cannot be guaranteed, and the solution should be discarded. Lyophilized powder is far more stable: unopened vials stored at −20°C retain potency for two years.

Request a certificate of analysis (COA) from the supplier. Legitimate research-grade peptide vendors provide HPLC and mass spectrometry data confirming the amino acid sequence and purity percentage. If a product labelled 'Selank' doesn't match the Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂ sequence at ≥95% purity, it's either mislabelled or improperly synthesised. Real Peptides includes third-party COA documentation with every batch specifically to eliminate this ambiguity.

Preclinical evidence suggests no. Studies in rodent models show that Selank Amidate maintains anxiolytic efficacy after 21 days of continuous administration without dose escalation or receptor downregulation. This contrasts sharply with benzodiazepines, which typically induce tolerance within 7–14 days. The mechanism appears related to Selank's indirect GABAergic modulation (receptor upregulation rather than direct agonism), which does not trigger compensatory receptor internalisation. Twice-daily dosing at 300 mcg per administration is common in extended anxiety research protocols.

They're structurally related but mechanistically distinct. Both are synthetic peptides derived from naturally occurring sequences (Selank from tuftsin, Semax from ACTH), and both cross the blood-brain barrier. However, Semax primarily enhances cognitive function through dopaminergic and cholinergic pathways, while Selank targets GABAergic and serotonergic anxiolytic mechanisms. Semax is better suited for focus and memory enhancement; Selank is better suited for anxiety reduction without sedation.

Discard it immediately. Cloudiness indicates protein aggregation or microbial contamination, both of which render the peptide biologically inactive and potentially unsafe. Properly reconstituted Selank Amidate peptide should be clear and colourless. Cloudiness most often results from improper mixing technique (vigorous shaking instead of gentle swirling) or temperature excursion during storage. Aggregated peptides cannot be restored to functional form through filtration or re-dissolution.

Structural degradation begins within 6–12 hours at ambient temperature (20–25°C), though visible changes may not appear for 24–48 hours. If the peptide was left out for fewer than 6 hours and shows no cloudiness, refrigerate it immediately and prioritise its use. Potency may be reduced by 10–20% but the peptide is likely still functional. Beyond 12 hours at room temperature, assume significant degradation has occurred and replace the solution. Temperature-stable peptide formulations do not exist for Selank Amidate. Refrigeration is non-negotiable.

No. Assume the peptide is the amidate form unless explicitly stated otherwise. In peptide synthesis, the amide modification is the default terminal protection used during solid-phase synthesis. Removing it requires deliberate chemical steps that serve no research or therapeutic purpose. If a supplier lists 'Selank' without specifying 'amidate', it's shorthand for the standard heptapeptide with the C-terminal amide cap.

Verify peptide authenticity and storage conditions first. Selank amidate from suppliers without third-party purity verification may contain degraded peptide, incorrect sequences, or insufficient amidate modification. Request a certificate of analysis (CoA) showing HPLC purity above 98% and mass spectrometry confirmation of the amidated C-terminus. If the peptide is verified and storage was correct, the issue may be individual variability in BDNF response or baseline GABAergic tone. Approximately 15–20% of subjects in animal studies show minimal anxiolytic response to selank despite confirmed peptide activity. Alternative mechanisms like P21 for cognitive resilience or Dihexa for synaptic plasticity may produce better results in non-responders.

Discard it immediately and do not administer. Cloudiness, discoloration (yellow, brown, or pink tint), or visible particulates indicate bacterial contamination, oxidative degradation, or peptide aggregation. All of which render the solution unsafe and ineffective. Selank amidate in bacteriostatic water should remain clear and colorless throughout its 28-day refrigerated shelf life. Contamination most commonly occurs from non-sterile reconstitution technique (failing to swab the vial stopper with 70% isopropyl alcohol) or repeated needle punctures without maintaining aseptic conditions. If contamination occurs within the first 72 hours, the likely cause is non-bacteriostatic water or compromised vial integrity during shipping.

Choose Selank peptide if the research question involves chronic anxiety management, cognitive performance under stress, or neuroprotection. Contexts where benzodiazepine sedation, tolerance, and withdrawal would confound results. Benzodiazepines produce faster onset (minutes) but impair memory consolidation and psychomotor speed within the first dose. Selank peptide takes 3–7 days to reach steady-state anxiolytic effects, but those effects don't degrade over time and don't impair learning. If your protocol requires acute intervention (panic attack models, for example), benzodiazepines remain the appropriate tool. If you're studying sustained emotional regulation or stress resilience, Selank peptide is the cleaner model.

No. Administer the standard dose at the next scheduled time and resume the regular protocol. Selank amidate does not produce withdrawal symptoms or rebound anxiety following a missed dose. Its mechanism is modulatory rather than suppressive, so sudden discontinuation does not trigger compensatory upregulation like benzodiazepines. Doubling the dose increases the risk of transient side effects (dizziness, nasal irritation, mild headache) without producing proportionally greater anxiolytic benefit. The dose-response curve is relatively flat above 600 mcg, meaning higher doses do not enhance efficacy meaningfully.

Consider Semax instead. Or study both in parallel. Selank peptide and Semax Amidate Peptide are structurally related (both derived from endogenous regulatory peptides) but have different primary mechanisms. Semax is more dopaminergic and nootropic, enhancing attention, working memory, and processing speed with minimal anxiolytic effect. Selank peptide is more serotonergic and calming, with secondary cognitive benefits that appear under stress conditions rather than baseline performance. If your hypothesis involves stress-buffering (maintaining cognitive function during distraction or time pressure), Selank peptide is the appropriate compound. If you're studying raw cognitive output in the absence of stress, Semax is the better fit. Both are available from Real Peptides as amidate formulations, and both are synthesized under the same small-batch, sequence-verified protocols that ensure consistent results across studies.

Switch to subcutaneous administration or reduce the concentration of the reconstituted solution. Nasal irritation is typically caused by one of three factors: excessive benzyl alcohol concentration in the bacteriostatic water (concentrations above 1% can irritate mucosa), overly acidic or basic pH (should be 5.5–7.0), or too-frequent dosing without allowing mucosal recovery. Subcutaneous injection bypasses nasal mucosa entirely and produces equivalent systemic bioavailability with slightly delayed onset. Alternatively, diluting the peptide solution to a lower concentration (e.g., 200 mcg per 0.1 mL instead of 600 mcg per 0.1 mL) reduces the volume of excipients delivered per dose.

Discard it. Peptides are proteins, and proteins denature irreversibly above their thermal stability threshold. For most peptides, that threshold is 8–10°C. An overnight exposure to room temperature (20–25°C) means the peptide's tertiary structure has unfolded, and the amino acid sequence is no longer functionally active. You cannot reverse this by refrigerating it again. The damage is structural, not chemical. Cloudy appearance, precipitate formation, or color change are all visible signs of denaturation, but degradation can occur even when the solution looks clear. For research integrity, any temperature-compromised vial must be discarded and replaced. This is why cold chain documentation matters when sourcing peptides. A single shipping delay above refrigeration range can render an entire batch useless before it arrives.